News >

Maintenance Rituximab Post-ASCT Associated With Improved OS in MCL

Jason Harris
Published: Tuesday, Sep 19, 2017

Matthew G. Mei, MD
Matthew G. Mei, MD
Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation (ASCT) as treatment for mantle cell lymphoma (MCL) had a survival advantage, according to results from a retrospective single-center study.

The 5-year cumulative incidence of relapse was 41% (95% CI, 34-48), with a continuous pattern of relapse events occurring at a median of 2.1 years after ASCT. A total of 83 relapses occurred at a median of 2.1 years posttransplant. Fourteen of 83 patients who relapsed subsequently underwent allogeneic transplant. Secondary malignancies occurred in 14 patients (7%), of which 5 were therapy-related myelodysplastic syndrome or acute myelogenous leukemia (3%). Nonrelapse mortality, defined as any death without a prior relapse, occurred in 16 patients (8%), and was a result of a secondary malignancy in 10 patients (5%).
Mei MG, Cao TM, Song JY, et a. Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab. Biol Blood Marrow Transplant [published online ahead of print July 18, 2017]. doi:10.1016/j.bbmt.2017.07.006.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication